Actinium Pharmaceuticals, Inc. - FORM 10-K - EX-10.62 - AMENDMENT TO ACTINIUM PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK, DA - March 16, 2017

Attached files

file filename
EX-10.60 - AMENDMENT TO EMPLOYMENT AGREEMENT - DRAGAN CICIC - Actinium Pharmaceuticals, Inc.f10k2016ex10lx_actinium.htm
10-K - ANNUAL REPORT - Actinium Pharmaceuticals, Inc.f10k2016_actiniumpharma.htm
EX-32.2 - CERTIFICATION - Actinium Pharmaceuticals, Inc.f10k2016ex32ii_actinium.htm
EX-32.1 - CERTIFICATION - Actinium Pharmaceuticals, Inc.f10k2016ex32i_actinium.htm
EX-31.2 - CERTIFICATION - Actinium Pharmaceuticals, Inc.f10k2016ex31ii_actinium.htm
EX-31.1 - CERTIFICATION - Actinium Pharmaceuticals, Inc.f10k2016ex31i_actinium.htm
EX-23.1 - CONSENT OF GBH CPAS, PC - Actinium Pharmaceuticals, Inc.f10k2016ex23i_actinium.htm
EX-10.66 - INDEMNIFICATION AGREEMENT - MARK S. BERGER - Actinium Pharmaceuticals, Inc.f10k2016ex10lxvi_actinium.htm
EX-10.65 - CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT - Actinium Pharmaceuticals, Inc.f10k2016ex10lxv_actinium.htm
EX-10.64 - OFFER LETTER - DR. MARK S. BERGER - Actinium Pharmaceuticals, Inc.f10k2016ex10lxiv_actinium.htm
EX-10.63 - WARRANT TO PURCHASE COMMON STOCK OF ACTINIUM PHARMACEUTICALS, INC., DATED MARCH - Actinium Pharmaceuticals, Inc.f10k2016ex10lxiii_actinium.htm
EX-10.61 - AMENDMENT TO ACTINIUM PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK, DA - Actinium Pharmaceuticals, Inc.f10k2016ex10lxi_actinium.htm
EX-10.59 - FIFTH AMENDMENT TO THE 2013 AMENDED AND RESTATED STOCK PLAN - Actinium Pharmaceuticals, Inc.f10k2016ex10lix_actinium.htm

Exhibit 10.62

AMENDMENT
TO
ACTINIUM PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK

Pursuant to Section 9(a) of the Warrant to Purchase Common Stock of (the “Warrant”) of Actinium Pharmaceuticals, Inc. (the “Company”), dated January 31, 2012, issued to Amrosan LLC in the amount of 99,617 warrant shares, the Board of Directors of the Company has duly adopted a resolution approving this Amendment to the Warrant to extend the term of the Warrant to February 11, 2022 as follows:

1.       Section 1 of the Warrant is hereby amended to read in its entirety as follows:

“Term of Warrant. Subject to the terms and conditions set forth herein, this Warrant shall be exercisable, in whole or in part, during the term commencing (“Issuance Date”) January 31, 2012 (the “Warrant Issue Date”), and ending at 5:00 p.m., Eastern Time on February 11, 2022 and shall be void thereafter.”

2.       All other terms and provisions of the Warrant shall remain unchanged and in full force and effect as written.

IN WITNESS WHEREOF, this Amendment to the Warrant is made effective this 14th day of March, 2017.

 

  ACTINIUM PHARMACEUTICALS, INC.
     
  By: /s/ Kaushik J. Dave
  Name: Kaushik J. Dave
  Title: Chief Executive officer

 

Actinium Pharmaceuticals, Inc. Reports